News As Blenrep returns, GSK adds another ADC to cancer pipeline GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.
News GSK's Blenrep's back in US, but with a narrower label Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.
News Alector ditches GSK-partnered dementia drug and cuts staff Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.
News GSK will file oral carbapenem for complicated UTIs this year GSK and Spero's cabapenem tebipenem is the first oral antibiotic in the class to show efficacy in complicated urinary tract infections.
News ViiV's bimonthly HIV PrEP jab cleared for use by NHS ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.
R&D Sponsored Why conditions like UTI call for new antibiotics Exploring the growing threat of UTIs, the need for new antibiotics, and GSK’s role in advancing targeted treatments.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
